Soluble CD14 and


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
11 2019
Historique:
received: 10 04 2019
accepted: 06 08 2019
pubmed: 1 9 2019
medline: 9 7 2020
entrez: 1 9 2019
Statut: ppublish

Résumé

Experimental studies have implicated soluble (s)CD14, an effector of lipopolysaccharide-induced inflammation, in insulin resistance, but its role in human metabolic endotoxemia has not been studied. We evaluated sCD14 in relation to dysglycemia in older adults and how this compares to other markers of inflammation. We investigated associations of sCD14, interleukin-6 (IL-6), CRP, and white blood cell (WBC) count with insulin resistance (quantitative insulin-sensitivity check index and HOMA 2 of insulin resistance) and incident type 2 diabetes in a population-based cohort of older adults. We also assessed the causal role of sCD14 in insulin resistance using an instrumental variable approach by Mendelian randomization. After adjustment for conventional risk factors, each of the four biomarkers showed positive cross-sectional associations with both insulin resistance measures. These associations persisted after mutual adjustment for all markers except sCD14. Over a median follow-up of 11.6 years, 466 cases of diabetes occurred. All biomarkers except sCD14 were positively associated with diabetes, although only WBC count remained associated (hazard ratio 1.43 per doubling [95% CI 1.07, 1.90]) after mutual adjustment. Instrumental variable analysis did not support a causal role for sCD14 in insulin resistance. Among older adults, sCD14 was associated with insulin resistance, but this disappeared after adjustment for other biomarkers, showed no evidence of a causal basis, and was not accompanied by a similar association with diabetes. IL-6, CRP, and WBC count were each associated with insulin resistance and diabetes, WBC count most robustly. These findings do not support a central role for sCD14, but they highlight the preeminence of WBC count as an inflammatory measure of diabetes risk in this population.

Identifiants

pubmed: 31471378
pii: dc19-0723
doi: 10.2337/dc19-0723
pmc: PMC6804612
doi:

Substances chimiques

Biomarkers 0
CD14 protein, human 0
IL6 protein, human 0
Interleukin-6 0
Lipopolysaccharide Receptors 0

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2075-2082

Subventions

Organisme : NHLBI NIH HHS
ID : U01 HL080295
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL130114
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200800007C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55222
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85086
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK111022
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL071862
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85082
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85083
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL135413
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85080
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85081
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200036C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85079
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG023629
Pays : United States

Informations de copyright

© 2019 by the American Diabetes Association.

Références

Diabetes. 2001 Oct;50(10):2384-9
pubmed: 11574423
Nature. 2006 Dec 14;444(7121):860-7
pubmed: 17167474
Diabetes. 2008 Jun;57(6):1470-81
pubmed: 18305141
JAMA. 2015 Sep 8;314(10):1021-9
pubmed: 26348752
J Clin Invest. 2017 Jan 3;127(1):14-23
pubmed: 28045399
J Biol Chem. 2000 Nov 17;275(46):36430-5
pubmed: 10960472
Ann Epidemiol. 1991 Feb;1(3):263-76
pubmed: 1669507
Mol Nutr Food Res. 2016 Jan;60(1):103-9
pubmed: 26114238
Clin Chem. 1997 Jan;43(1):52-8
pubmed: 8990222
PLoS One. 2008;3(10):e3583
pubmed: 18974833
Ann Epidemiol. 1995 Jul;5(4):278-85
pubmed: 8520709
J Clin Invest. 2001 Aug;108(3):485-93
pubmed: 11489942
J Immunol. 1996 Jun 1;156(11):4384-90
pubmed: 8666811
Ann Epidemiol. 1995 Jul;5(4):270-7
pubmed: 8520708
J Clin Invest. 2016 Jan;126(1):12-22
pubmed: 26727229
Clin Chem. 1995 Feb;41(2):264-70
pubmed: 7874780
Biochimie. 2016 May;124:11-20
pubmed: 26133659
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2744-8
pubmed: 7681988
Life Sci. 2008 Sep 26;83(13-14):502-10
pubmed: 18761356
J Clin Invest. 2011 Jun;121(6):2126-32
pubmed: 21633181
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Clin Endocrinol Metab. 2003 Apr;88(4):1780-4
pubmed: 12679473
J Immunol. 2004 Apr 1;172(7):4470-9
pubmed: 15034063
J Clin Invest. 2017 Jan 3;127(1):83-93
pubmed: 28045401
Front Cell Infect Microbiol. 2013 Jul 24;3:32
pubmed: 23898465
Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):158-64
pubmed: 23162014
Diabetes Care. 2010 Apr;33(4):804-10
pubmed: 20097779
Diabetes. 2011 Aug;60(8):2179-86
pubmed: 21700881
Diabetes Care. 2012 Feb;35(2):415-23
pubmed: 22148099
Diabetes. 2005 Jul;54(7):1914-25
pubmed: 15983190
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
pubmed: 10902785
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Mol Metab. 2013 Jul 04;2(3):281-91
pubmed: 24049740
Diabetes Care. 1998 Dec;21(12):2191-2
pubmed: 9839117
PLoS One. 2010 Oct 18;5(10):e13405
pubmed: 20976133
J Clin Invest. 2017 Jan 3;127(1):74-82
pubmed: 28045400
Nutr Metab Cardiovasc Dis. 2016 Jan;26(1):1-8
pubmed: 26719220
JAMA. 2001 Jul 18;286(3):327-34
pubmed: 11466099
Diabetes. 2003 Mar;52(3):812-7
pubmed: 12606524

Auteurs

Sanyog G Shitole (SG)

San Francisco VA Health Care System, San Francisco, CA.
University of California, San Francisco, San Francisco, CA.

Mary L Biggs (ML)

University of Washington, Seattle, WA.

Alexander P Reiner (AP)

University of California, San Francisco, San Francisco, CA.

Kenneth J Mukamal (KJ)

Beth Israel Deaconess Medical Center, Boston, MA.
Harvard Medical School, Boston, MA.

Luc Djoussé (L)

Harvard Medical School, Boston, MA.
Brigham and Women's Hospital, Boston, MA.
VA Boston Healthcare System, Boston, MA.

Joachim H Ix (JH)

University of California San Diego School of Medicine, La Jolla, CA.
VA San Diego Healthcare System, San Diego, CA.

Joshua I Barzilay (JI)

Kaiser Permanente Georgia Region, Atlanta, GA.
Emory University School of Medicine, Atlanta, GA.

Russell P Tracy (RP)

University of Vermont, Burlington, VT.

David Siscovick (D)

New York Academy of Medicine, New York, NY.

Jorge R Kizer (JR)

San Francisco VA Health Care System, San Francisco, CA jorge.kizer@ucsf.edu.
University of California, San Francisco, San Francisco, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH